CAPUA, Italy, October 31, 2018 /PRNewswire/ --
Capua BioServices, Europe's largest, independent provider of high quality services in microbial contract development and manufacturing services for pharma and food industry, has announced the completion of the renovation of one of the recovery and purification plants, at its facility in Capua, Italy.
(Logo: https://mma.prnewswire.com/media/777068/Capua_Logo.jpg )
In order to continuously add value to its growing customer base, Capua BioServices has designed its entire facility to be remarkably flexible; from lab - to development - to commercial production scale. This specific investment to renew this existing plant, is focused on further increasing its multi-purpose manufacturing capabilities for pharma-grade manufacturing. The strength of this new set up is that it can be used to process - via an integrated state-of-the-art modular tangential-flow-filtration system - serval thousands of litres to tens of thousands of litres in a very time- and space-efficient manner, still leaving further room for expansion.
"We are very happy that our shareholder, Livia Group, is supporting our investment in this field. There is a strong commitment from us to increasingly support the developers of advanced therapies throughout the dynamics of clinical development, while navigating towards seamless transition to commercial production," said Sabine Decker, Chief Operating Officer of Capua BioServices. "We are convinced that with this refurbishment and expansion of this installation which will house a large diversity of unit operations, we can provide a broader offer to our customers and assist them to rapidly deliver clinical candidates to patients."
Capua BioServices is a global provider of high-quality services in the field of custom microbial process development and manufacturing. Capua offers dedicated solutions for the process development and manufacturing of proteins, enzymes, antibodies/fragments and specialty compounds for applications in pharmaceutical and food markets.
As the largest, independent, beta-lactam free microbial contract manufacturing facility in Europe, it has an extensive experience in working with a variety of bacterial, yeast and fungal systems. Located near Naples, in the south of Italy, it has a total fermentation capacity of about 1400 m3 spread over two separate fermentation areas.
Capua has dedicated areas for pharmaceutical manufacturing as well as food-grade manufacturing and complies to cGMP (FDA and EMA approved), GFSI (FSSC 22.000) and ISO standards (14001).
CONTACT: Elise Mous, firstname.lastname@example.org, +39-0823-628-323